8th Bacteriophage Therapy Summit 2026

Memo

This is the only industry-led, industry dedicated meeting, tackling the real-world challenges preventing bacteriophage therapies from reaching patients - from manufacturing and clinical trial design to investment models and evolving regulatory expectations. As regulators clarify approval pathways, phage’s make it into late-stage clinical trials, and investment momentum returns, 2026 marks a pivotal moment for the phage field to shift from promise to practical delivery. If you are determined to ensure the community can bring precise, scalable and commercially viable products to market, this is your one-stop platform to make it happen. Over three days, you will connect directly with C-level experts, decision-makers and leading minds across biotech, pharma, academia, policy and investment who are defining how phage-based products move through approval and adoption. Discover new data, actionable frameworks and the collaborations that will shape the next generation of antibacterial solutions. Join us to help translate phage science into sustainable, patient-ready therapies and position yourself at the centre of this fast-maturing field. URLs:Tickets: https://go.evvnt.com/3358874-2?pid=5569 Brochure: https://go.evvnt.com/3358874-3?pid=5569  Date and Time: Tue, 24 Mar 2026 08:00 - Thu, 26 Mar 2026 17:00 Venue details: Novotel London West, 1 Shortlands Hammersmith International Ctre, London, England, W6 8DR, United Kingdom Prices:Phage Developer Pricing - Conference + 2 Workshops: GBP 3197.00,Phage Developer Pricing - Conference + 1 Workshop: GBP 2478.00,Phage Developer Pricing - Conference Only: GBP 2299.00,Academic Pricing - Conference + 2 Workshops: GBP 2547.00,Academic Pricing - Conference + 1 Workshop: GBP 2223.00,Academic Pricing - Conference Only: GBP 1899.00,Service Provider Pricing - Conference + 2 Workshops: GBP 3997.00,Service Provider Pricing - Conference + 1 Workshop: GBP 3448.00,Service Provider Pricing - Conference Only: GBP 2899.00 Speakers: Deborah Birx, Chief Executive Officer, Armata Pharmaceuticals , Ben Swift, Lead Scientist, Carus Animal Health, Dansh Malik, Professor - Industrial Biotechnology, Crest Loughborough University, Ryszard Miedzybrodzki, Head of Lab, Hirszfeld Institute of Immunology and Experimental Therapy, Francesca Hodges, Innovation Lead - Future Medicines, Medicines Discovery and Medicines Manufacturing, Innovate UK, Alexander Sulakvelidze, President and Chief Executive Officer, Intralytix inc., Raquel Rodriguez Alonso, Policy Officer, JRC - European Comission, Mark Sutton, Professor for Antimicrobial Therapy and Scientific Leader at UKHSA, Kings College University, Gregorio Iraola, Chief Executive Officer, Kinzbio, Jason Clark, Chief Scientific Officer, NexaBiome, Antonia Scobie, Consultant and Research Lead - Bone Infection Unit, NHS, Stephanie Lesage, Co-founder and Chief Executive Officer, Oxford Silk Phage Technologies, William Marsh, Chief Executive Officer, Phagefarm, Matthew Tebeau, Chief Operating Officer, Phagelux AgriHealth, Mimi Yen, Chief Executive Officer, PhagePro, Amanda Burkardt, Chief Executive Officer, Phiogen Pharma, Matt Cummings, Chief Executive Officer, Precisio Biotix Therapeutics , Jean-Paul Pirnay, Head of Laboratory, Queen Astrid Military Hospital, Jonas Hink, Chief Medical Officer, SNIPR Biome, Sofia Corte-Real, Deputy Chief Executive Officer, TechnoPhage SA, Subhendu Basu, Chief Executive Officer, Telum Therapeutics , Colin Brown, Head of Antimicrobial Resistance and Healthcare Associated Infections and Deputy Director: Epidemic and Emerging Infections, The UK Health Security Agency, Catherine Rees, Professor of Microbiology and Division Head, University of Nottingham